PE20080521A1 - DERIVADOS DE ESPIROCETAL DE ANILLO FUSIONADO COMO INHIBIDORES DEL COTRANSPORTADOR Na+-GLUCOSA 2 (SGLT2) - Google Patents

DERIVADOS DE ESPIROCETAL DE ANILLO FUSIONADO COMO INHIBIDORES DEL COTRANSPORTADOR Na+-GLUCOSA 2 (SGLT2)

Info

Publication number
PE20080521A1
PE20080521A1 PE2007000972A PE2007000972A PE20080521A1 PE 20080521 A1 PE20080521 A1 PE 20080521A1 PE 2007000972 A PE2007000972 A PE 2007000972A PE 2007000972 A PE2007000972 A PE 2007000972A PE 20080521 A1 PE20080521 A1 PE 20080521A1
Authority
PE
Peru
Prior art keywords
spirocetal
sglt2
inhibitors
glucose
carrier
Prior art date
Application number
PE2007000972A
Other languages
English (en)
Inventor
Tsutomu Sato
Yoshihito Ohtake
Masahiro Nishimoto
Takashi Emura
Takamitsu Kobayashi
Marina Yamaguchi
Kyouko Takami
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38981587&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080521(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of PE20080521A1 publication Critical patent/PE20080521A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE ESPIROCETAL DE ANILLO FUSIONADO DE FORMULA (I) DONDE R1, R2, R3 Y R4 SON CADA UNO H, ALQUILO(C1-C6) OPCIONALMENTE SUSTITUIDO CON Ra, O ARALQUILO(C7-C14) OPCIONALMENTE SUSTITUIDO CON Rb O C(=O)Rx, DONDE Ra ES HALOGENO, OH, CN, NITRO, ENTRE OTROS; Rb ES HALOGENO, OH, CN, CARBOXI, ENTRE OTROS; Rx ES ALQUILO(C1-C6), ALCOXI(C1-C6), ENTRE OTROS; n ES 1 O 2; Ar ES UN COMPUESTO DE FORMULA (c), (d), ENTRE OTROS, DONDE Re ES ARALQUILO(C7-C14) O HETEROARILALQUILO(C5-C12); W ES S, O U NRh, DONDE Rh ES H O ALQUILO(C1-C6). SON COMPUESTOS PREFERIDOS: (3'R,4'S,5S,5'S,6'R)-3-[(4-ETILFENIL)METIL]-6'-HIDROXIMETIL-3',4',5',6'-TETRAHIDRO-ESPIRO[TIENO[2,3,f]ISOBENZOFURAN-5(7H),2'-[2H]PIRAN]-3',4',5'-TRIOL, (3'R,4'S,5'S,6'R,7S)-1-[(4-ETILFENIL)METIL]-6'-HIDROXIMETIL-3',4',5',6'-TETRAHIDRO-ESPIRO[FURO[3,4,f]INDOL-7(5H),2'-[2H]PIRAN]-3',4',5'-TRIOL, (1S,3'R,4'S,5'S,6'R)-8-[(4-ETILFENIL)METIL]-3,3',4,4',5',6'-HEXAHIDRO-6'-HIDROXIMETIL-ESPIRO[2-OXA-9-TIA-FLUORENO-1,2'-[2H]PIRAN]-3',4',5'-TRIOL, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DEL COTRANSPORTADOR Na+-GLUCOSA 2 (SGLT2) SIENDO UTILES EN EL TRATAMIENTO DE DIABETES, HIPERGLUCEMIA, OBESIDAD
PE2007000972A 2006-07-27 2007-07-26 DERIVADOS DE ESPIROCETAL DE ANILLO FUSIONADO COMO INHIBIDORES DEL COTRANSPORTADOR Na+-GLUCOSA 2 (SGLT2) PE20080521A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006205242 2006-07-27

Publications (1)

Publication Number Publication Date
PE20080521A1 true PE20080521A1 (es) 2008-06-13

Family

ID=38981587

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000972A PE20080521A1 (es) 2006-07-27 2007-07-26 DERIVADOS DE ESPIROCETAL DE ANILLO FUSIONADO COMO INHIBIDORES DEL COTRANSPORTADOR Na+-GLUCOSA 2 (SGLT2)

Country Status (18)

Country Link
US (1) US8207134B2 (es)
EP (1) EP2048152A4 (es)
JP (1) JP5165565B2 (es)
KR (1) KR20090033911A (es)
CN (1) CN101495494A (es)
AR (1) AR062110A1 (es)
AU (1) AU2007277704A1 (es)
BR (1) BRPI0715248A2 (es)
CA (1) CA2658921A1 (es)
CL (1) CL2007002186A1 (es)
IL (1) IL196585A0 (es)
MX (1) MX2009000579A (es)
NO (1) NO20090173L (es)
PE (1) PE20080521A1 (es)
RU (1) RU2009106866A (es)
TW (1) TWI432446B (es)
WO (1) WO2008013277A1 (es)
ZA (1) ZA200900706B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4260770B2 (ja) 2005-05-09 2009-04-30 任天堂株式会社 ゲームプログラムおよびゲーム装置
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2733795C (en) 2008-08-28 2013-12-31 Pfizer Inc. Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
DK2496583T3 (en) 2009-11-02 2015-02-02 Pfizer Dioxa-bicyclo [3.2.1] octane-2,3,4-triol DERIVATIVES
WO2011070592A2 (en) 2009-12-09 2011-06-16 Panacea Biotec Ltd. Novel sugar derivatives
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
ITMI20110362A1 (it) * 2011-03-09 2012-09-10 F I S Fabbrica Italiana Sint P A Procedimento per la preparazione di 1-(6-metilpiridin-3-il)-2-[4-(metilsolfonil)fenil]etanone, un intermedio dell'etoricoxib.
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013038429A2 (en) 2011-09-13 2013-03-21 Panacea Biotec Ltd. Novel sglt inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN104987314A (zh) * 2015-07-14 2015-10-21 佛山市赛维斯医药科技有限公司 含苯并异恶唑和末端硝基苄基类结构的化合物及其用途
CN105001174A (zh) * 2015-07-14 2015-10-28 佛山市赛维斯医药科技有限公司 含苯并异恶唑和末端腈基苄基类结构的化合物及其用途
CN110483475B (zh) * 2019-08-15 2020-11-27 绍兴文理学院 一种氧化银催化法制备苯并噻吩类化合物的方法
CN110483476B (zh) * 2019-08-15 2020-11-27 绍兴文理学院 一种催化法制备苯并硒吩类化合物的工艺
CN112574226A (zh) * 2020-12-15 2021-03-30 海门华祥医药科技有限公司 5,6-亚甲基二氧基吲哚的制备方法
CN116178143B (zh) * 2021-11-26 2024-10-01 中国科学院大连化学物理研究所 一种1,4-萘二甲酸/酯、1,4-萘二甲酸衍生物及其制备方法和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470845A (en) 1992-10-28 1995-11-28 Bristol-Myers Squibb Company Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
JP2000080041A (ja) 1998-03-09 2000-03-21 Tanabe Seiyaku Co Ltd 医薬組成物
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6627611B2 (en) 2000-02-02 2003-09-30 Kotobuki Pharmaceutical Co Ltd C-glycosides and preparation of thereof as antidiabetic agents
EP1270584B1 (en) 2000-03-17 2005-12-07 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives
US6774112B2 (en) 2001-04-11 2004-08-10 Bristol-Myers Squibb Company Amino acid complexes of C-aryl glucosides for treatment of diabetes and method
DE10231370B4 (de) 2002-07-11 2006-04-06 Sanofi-Aventis Deutschland Gmbh Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
TWI254635B (en) 2002-08-05 2006-05-11 Yamanouchi Pharma Co Ltd Azulene derivative and salt thereof
ES2567571T3 (es) 2003-03-14 2016-04-25 Astellas Pharma Inc. Derivados de C-glucósido y sales de los mismos
SI1651658T2 (sl) 2003-08-01 2020-12-31 Mitsubishi Tanabe Pharma Corporation Nove spojine, ki imajo inhibitorno aktivnost proti transporterju, ki je odvisen od natrija
WO2005012242A2 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica Nv Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
EA010655B1 (ru) 2003-08-01 2008-10-30 Янссен Фармацевтика Н.В. Замещенные индазол-о-глюкозиды
CA2549025A1 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indole-o-glucosides
EP1679965A4 (en) 2003-08-01 2009-05-27 Janssen Pharmaceutica Nv SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES
WO2005085237A1 (ja) * 2004-03-04 2005-09-15 Kissei Pharmaceutical Co., Ltd. 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
RU2387663C2 (ru) 2004-03-04 2010-04-27 Киссеи Фармасьютикал Ко., Лтд. Конденсированные гетероциклические производные, содержащие их медицинские композиции и их медицинское применение
CN103467423B (zh) 2004-03-16 2016-03-16 贝林格尔.英格海姆国际有限公司 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
DE102004034690A1 (de) 2004-07-17 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
CA2574451A1 (en) 2004-07-27 2006-02-02 Boehringer Ingelheim International Gmbh D-glucopyranosyl phenyl-substituted cyclene, medicaments containing these compounds, their use, and method for the production thereof
WO2006018150A1 (de) 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
DE102004048388A1 (de) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO2006054629A1 (ja) * 2004-11-18 2006-05-26 Kissei Pharmaceutical Co., Ltd. １－置換－３－（β－Ｄ－グリコピラノシル）含窒素ヘテロ環化合物、及びそれを含有する医薬
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
WO2007140191A2 (en) 2006-05-23 2007-12-06 Theracos, Inc. Glucose transport inhibitors and methods of use
US7795228B2 (en) 2006-12-28 2010-09-14 Theracos, Inc. Spiroheterocyclic glycosides and methods of use

Also Published As

Publication number Publication date
EP2048152A4 (en) 2013-01-23
WO2008013277A1 (fr) 2008-01-31
CN101495494A (zh) 2009-07-29
CL2007002186A1 (es) 2008-02-01
NO20090173L (no) 2009-04-27
TWI432446B (zh) 2014-04-01
US20100234609A1 (en) 2010-09-16
AU2007277704A1 (en) 2008-01-31
KR20090033911A (ko) 2009-04-06
TW200821323A (en) 2008-05-16
US8207134B2 (en) 2012-06-26
IL196585A0 (en) 2009-11-18
MX2009000579A (es) 2009-01-27
CA2658921A1 (en) 2008-01-31
JPWO2008013277A1 (ja) 2009-12-17
ZA200900706B (en) 2010-05-26
BRPI0715248A2 (pt) 2013-06-04
JP5165565B2 (ja) 2013-03-21
AR062110A1 (es) 2008-10-15
RU2009106866A (ru) 2010-09-10
EP2048152A1 (en) 2009-04-15

Similar Documents

Publication Publication Date Title
PE20080521A1 (es) DERIVADOS DE ESPIROCETAL DE ANILLO FUSIONADO COMO INHIBIDORES DEL COTRANSPORTADOR Na+-GLUCOSA 2 (SGLT2)
PE20080731A1 (es) Derivados espirocetales comoinhibidores de sglt2
PE20091014A1 (es) Compuestos espiro y uso farmaceutico de los mismos
SI1838698T1 (sl) Derivati pirimidina kot agonisti gcpr
PE20120002A1 (es) Derivados de benceno sustituido con glucopiranosilo como inhibidores de sglt2
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
PE20080182A1 (es) Derivados pirrolo-quinoxalinona como antibacterianos
PE20020510A1 (es) DERIVADOS DE AZEPILO [4,5b] INDOLINA SUSTITUIDOS COMO LIGANDOS DE LOS RECEPTORES DE SEROTONINA (5-HT)
PE20141827A1 (es) Inhibidores de proteinas quinasas
AR053739A1 (es) Compuestos espiro condensados como inhibidores de la aldosterona sintasa
PE20080344A1 (es) Compuestos 8-azabiciclo[3.2.1]oct-8-il-1,2,3,4-tetrahidroquinolina sustituidos como inhibidores 11b-hsd1
PE20061096A1 (es) Derivados de oxiindol como agonistas 5-ht4
TW200720266A (en) Benzodioxane and benzodioxolan derivatives and uses thereof
PE20171640A1 (es) Analogos de nucleotidos sustituidos
AR044038A1 (es) Compuestos de pirazol e imidazol biciclicos como ligandos de receptor cannabinoide, composiciones farmaceuticas y usos de los mismos
WO2008062905A3 (en) Heteromonocyclic compound and use thereof
PE20121469A1 (es) Inhibidores de n1- pirazoloespirocetona acetil-coa carboxilasa
PE20110845A1 (es) Nuevos compuestos heterociclicos nitrogenados, preparacion de los mismos y utilizacion de los mismos como medicamentos antibacterianos
PE20141556A1 (es) Derivados de etinilo como moduladores alostericos de mglur5
PE20121158A1 (es) Derivados de feniletinilo como moduladores alostericos positivos (map)
PE20060590A1 (es) COMPUESTOS ESTEROIDALES 15ß-SUSTITUIDOS CON ACTIVIDAD SELECTIVA DEL RECEPTOR DE ESTROGENOS
PE20120219A1 (es) Inhibidores de beta-secretasa
AR065128A1 (es) Derivados de 2-aminooxazolinas como ligandos taar1. procesos de obtencion, composiciones farmaceuticas y usos
PE20110152A1 (es) Nuevos derivados de sulfamida sustituida
PE20070793A1 (es) Compuestos triciclicos que contienen nitrogeno como agentes antibacterianos

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed